@hematologyadvisor.bsky.social🚨 New research from #SOHO2026 highlights long-term immune dysfunction in survivors of childhood hematologic malignancies (mostly B-ALL), years after completing therapy.
Source: @societyofhemonc.bsky.social #SOHO26
More here: https://bit.ly/4dv14r4
@hematologyadvisor.bsky.socialUpdated SUNMO trial data presented at #SOHO2026 shows Mosun-Pola outperforms standard of care (R-GemOx) in transplant-ineligible R/R LBCL! 🔬
🔹Median PFS: 11.6 vs 3.8 months (HR: 0.41)
🔹ORR: 70.3% vs 40.0%
🔹CR: 51.4% vs 24.3%
Link to the story: https://bit.ly/3SXmBBW
@hematologyadvisor.bsky.social📈 2-year data from the Phase 3 SURPASS-ET trial presented at #SOHO2026 shows continuous ropeginterferon alfa-2b (ropeg) delivers durable hematologic & molecular benefits for high-risk essential thrombocythemia!
More details: https://bit.ly/3TodPwU
@hematologyadvisor.bsky.socialResearch from #SOHO2026: The Phase 3 ECHO trial support frontline acalabrutinib + bendamustine–rituximab (ABR) for untreated mantle cell #Lymphoma!
Key takeaways:
• ~6 yrs vs. ~4 yrs median PFS favoring ABR over PBR
• 32% lower risk of progression or death
#SOHO26 🩸
More: https://bit.ly/4iiVXO8
@hematologyadvisor.bsky.social#SOHO2026: The addition of ianalumab to eltrombopag therapy provides patients with primary ITP with durable improvements in symptom burden and fatigue that persist even after eltrombopag discontinuation📊🩺
Source: The phase 3 VAYHIT2 trial #SOHO26
Link to article: https://bit.ly/4inSRbO
@hematologyadvisor.bsky.socialNew from #SOHO26! CALGB 10403 (C10403) protocol used in adolescents and young adults with acute lymphoblastic leukemia may be equally safe and effective in adults aged 40+!
Read the full article here: https://bit.ly/4yx5upH
@hematologyadvisor.bsky.social